Structure Therapeutics Q2 Loss Widens to $106M as R&D Costs Surge
GPCR has more than doubled off its 52-week low of $15.8.
Summary
Structure Therapeutics reported a Q2 net loss of $106.16 million, driven by a jump in operating expenses to $118.63 million as clinical trial activity ramped up. The company dosed the first patients in Phase 3 trials for its lead obesity drug, aleniglipron, and disclosed a $1.3 billion cash runway through 2028. Topline 72-week data from the ACCESS OLE study is expected in Q3 2026, with a new combination GLP-1/amylin agonist trial starting in Q4. The widening loss reflects the cost of advancing a pipeline that recently showed up to 16.2% weight loss in Phase 2b, but the cash position provides ample funding to reach key milestones without near-term dilution risk.
At the time of this announcement, GPCR was trading at $52.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.